The global Diabetes Drugs Market size was valued at USD 84.65 billion in 2024 and is expected to be worth around USD 177.74 ...

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea ...

Farxiga (dapagliflozin) is an orally administered, brand-name medication classified as a sodium-glucose co-transporter 2 (SGLT2 ... the potential for adverse effects. Therefore, monitor yourself or a ...

The National Institute for Nephrology Dialysis and Transplantation (NINDT) has planned a series of events to mark this ...

Gender Disparities in the Association of Low Dietary Protein Intake With Congestive Heart Failure: An Analysis of the NHANES Database 2017-2020 Receive the the latest news, research, and presentations ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

According to Avik Ray, MD, MS, a postdoctoral research fellow at Brigham and Women's Hospital, and colleagues, prior studies on the effects of GLP-1 receptor agonists and SGLT2 inhibitors on ...

Prediction is very difficult, especially about the future”; whether it is the Nobel laureate Niels Bohr or others who have ...

Slight body weight and systolic blood pressure reduction are important beneficial effects. Main adverse events of SGLT2 inhibitors are genital mycotic and urinary tract infections. Dapagliflozin ...

Back to Healio Sodium-glucose cotransporter 2, or SGLT2, inhibitors may be more cardioprotective for older adults, whereas glucagon-like peptide-1 receptor agonists may confer greater HbA1c ...

Although low-dose dapagliflozin was less effective in preventing hospitalization for heart failure, SGLT-2 inhibitors had similar cardiovascular outcomes in T2D. Canagliflozin and dapagliflozin ...

or in the the APC or APPROVE trials. Controversy about the mechanisms of potential cardiovascular side effects of COX inhibitors and NSAIDs persists. Intriguingly, the sulfone COX2 inhibitors ...